These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 25916085)

  • 21. Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Muto T; Sasaki H; Urabe K; Sueda T
    J Gastrointest Surg; 2013 Aug; 17(8):1429-39. PubMed ID: 23797881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
    Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.
    Kagedan DJ; Raju RS; Dixon ME; Shin E; Li Q; Liu N; Elmi M; El-Sedfy A; Paszat L; Kiss A; Earle CC; Mittmann N; Coburn NG
    HPB (Oxford); 2016 Apr; 18(4):339-47. PubMed ID: 27037203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy.
    Aoyama T; Yamamoto N; Kamiya M; Murakawa M; Tamagawa H; Sawazaki S; Numata M; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yukawa N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
    Anticancer Res; 2018 Aug; 38(8):4877-4882. PubMed ID: 30061263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
    Versteijne E; Suker M; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Eijck CH; van Tienhoven G;
    J Clin Oncol; 2020 Jun; 38(16):1763-1773. PubMed ID: 32105518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
    Hosoda K; Fukushima K; Shimizu A; Motoyama H; Kubota K; Notake T; Sugenoya S; Hayashi H; Yasukawa K; Kobayashi R; Soejima Y
    Oncology; 2021; 99(11):703-712. PubMed ID: 34515195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
    Nakai Y; Isayama H; Sasaki T; Sasahira N; Kogure H; Hirano K; Tsujino T; Ijichi H; Tateishi K; Tada M; Omata M; Koike K
    Jpn J Clin Oncol; 2010 Aug; 40(8):774-80. PubMed ID: 20462979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakamura H; Nakashima A; Sueda T
    Ann Surg; 2009 Dec; 250(6):950-6. PubMed ID: 19953713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
    Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
    In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer.
    Morita Y; Sakaguchi T; Kitajima R; Furuhashi S; Kiuchi R; Takeda M; Hiraide T; Shibasaki Y; Kikuchi H; Konno H; Takeuchi H
    BMC Cancer; 2019 May; 19(1):416. PubMed ID: 31046709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
    Shinkawa H; Uenishi T; Takemura S; Sakata C; Urata Y; Nozawa A; Hamano G; Kinoshita M; Kubo S
    Hepatogastroenterology; 2015; 62(137):169-74. PubMed ID: 25911890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.
    Fischer R; Breidert M; Keck T; Makowiec F; Lohrmann C; Harder J
    Saudi J Gastroenterol; 2012; 18(2):118-21. PubMed ID: 22421717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
    Maeda A; Boku N; Fukutomi A; Kondo S; Kinoshita T; Nagino M; Uesaka K
    Jpn J Clin Oncol; 2008 Mar; 38(3):227-9. PubMed ID: 18272475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
    Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
    BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
    Harada N; Shirabe K; Yoshizumi T; Ikegami T; Uchiyama H; Soejima Y; Yamashita Y; Saeki H; Oki E; Kawanaka H; Morita M; Ikeda T; Matsuura H; Okadome K; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Dec; 104(12):539-48. PubMed ID: 24693682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study.
    Sakamoto T; Kishino M; Murakami Y; Miyatani K; Hanaki T; Shishido Y; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Fujiwara Y
    Medicine (Baltimore); 2024 May; 103(21):e38292. PubMed ID: 38788030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
    Yang PC; Huang KW; Pua U; Kim MD; Li SP; Li XY; Liang PC
    Eur J Surg Oncol; 2020 May; 46(5):811-817. PubMed ID: 31839436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
    Tsuchiya N; Matsuyama R; Murakami T; Yabushita Y; Sawada Y; Kumamoto T; Endo I
    World J Surg; 2020 Aug; 44(8):2752-2760. PubMed ID: 32291503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
    Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
    Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.